Abeona Therapeutics (NASDAQ:ABEO) Stock Price Crosses Above 50-Day Moving Average – What’s Next?

26 Jun 2026, 21:00 by Teresa Graham · The Cerbat Gem

Abeona Therapeutics Inc. (NASDAQ:ABEO – Get Free Report)’s stock price passed above its fifty day moving average during trading on Wednesday . The stock has a fifty day moving average of $5.57 and traded as high as $5.84. Abeona Therapeutics shares last traded at $5.62, with a volume of 1,068,864 shares changing hands.

Analysts Set New Price Targets

ABEO has been the topic of several analyst reports. Stifel Nicolaus set a $17.00 price target on shares of Abeona Therapeutics in a research report on Tuesday, March 17th. Wall Street Zen upgraded Abeona Therapeutics from a “strong sell” rating to a “sell” rating in a research note on Monday, June 1st. Oppenheimer reaffirmed an “outperform” rating on shares of Abeona Therapeutics in a report on Monday, March 9th. Finally, HC Wainwright reiterated a “buy” rating and issued a $20.00 price target on shares of Abeona Therapeutics in a research note on Thursday, May 28th. Two analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company. According to data from MarketBeat, Abeona Therapeutics presently has an average rating of “Hold” and an average target price of $19.00.

View Our Latest Stock Analysis on ABEO

Abeona Therapeutics Trading Up 1.0%

The company has a market capitalization of $320.00 million, a price-to-earnings ratio of 5.79 and a beta of 1.35. The company has a current ratio of 5.89, a quick ratio of 5.70 and a debt-to-equity ratio of 0.03. The business’s 50 day moving average price is $5.58 and its two-hundred day moving average price is $5.23.

Abeona Therapeutics (NASDAQ:ABEO – Get Free Report) last released its quarterly earnings data on Wednesday, May 13th. The biopharmaceutical company reported ($0.30) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.33) by $0.03. The company had revenue of $8.72 million for the quarter, compared to analyst estimates of $4.57 million. On average, equities analysts predict that Abeona Therapeutics Inc. will post -0.79 earnings per share for the current fiscal year.

Insider Activity

In other news, insider Madhav Vasanthavada sold 5,450 shares of the company’s stock in a transaction on Tuesday, June 9th. The shares were sold at an average price of $5.30, for a total transaction of $28,885.00. Following the completion of the transaction, the insider directly owned 303,451 shares in the company, valued at approximately $1,608,290.30. This represents a 1.76% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, CEO Vishwas Seshadri sold 31,916 shares of the stock in a transaction on Tuesday, June 9th. The shares were sold at an average price of $5.30, for a total value of $169,154.80. Following the completion of the transaction, the chief executive officer owned 1,374,079 shares of the company’s stock, valued at $7,282,618.70. The trade was a 2.27% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The sale was made to cover tax withholding obligations related to the vesting of equity awards. In the last quarter, insiders have sold 182,784 shares of company stock valued at $994,940. 7.10% of the stock is currently owned by insiders.

Institutional Trading of Abeona Therapeutics

A number of hedge funds have recently made changes to their positions in ABEO. Goldman Sachs Group Inc. grew its holdings in shares of Abeona Therapeutics by 49.6% during the first quarter. Goldman Sachs Group Inc. now owns 200,450 shares of the biopharmaceutical company’s stock worth $954,000 after purchasing an additional 66,422 shares during the last quarter. Geode Capital Management LLC boosted its position in Abeona Therapeutics by 129.1% during the 2nd quarter. Geode Capital Management LLC now owns 1,105,862 shares of the biopharmaceutical company’s stock worth $6,282,000 after buying an additional 623,243 shares during the period. Creative Planning grew its holdings in Abeona Therapeutics by 43.0% during the 2nd quarter. Creative Planning now owns 14,310 shares of the biopharmaceutical company’s stock worth $81,000 after acquiring an additional 4,305 shares during the last quarter. JPMorgan Chase & Co. grew its holdings in Abeona Therapeutics by 255.6% during the 2nd quarter. JPMorgan Chase & Co. now owns 831,132 shares of the biopharmaceutical company’s stock worth $4,721,000 after acquiring an additional 597,373 shares during the last quarter. Finally, Legal & General Group Plc acquired a new position in Abeona Therapeutics in the 2nd quarter valued at approximately $27,000. 80.56% of the stock is owned by institutional investors and hedge funds.

About Abeona Therapeutics

(Get Free Report)

Abeona Therapeutics is a clinical‐stage biopharmaceutical company focused on the development and commercialization of gene and cell therapies for severe, life‐threatening rare diseases and oncology indications. Founded in 2014 and headquartered in Cleveland, Ohio, Abeona leverages proprietary viral and non‐viral delivery platforms to correct or compensate for underlying genetic deficiencies. The company’s research efforts target pediatric neurodegenerative disorders as well as debilitating dermatologic conditions with high unmet medical need.